-
Application of dexmedetomidine in cervical cancer surgery and its effect
on VAS score
- Zhang Ran, Xu Guoting
-
2022, 28(23):
3350.
DOI: 10.3760/cma.j.issn.1007-1245.2022.23.023
-
Asbtract
(
)
-
References |
Related Articles |
Metrics
Objective To observe and analyze the effect of dexmedetomidine in cervical cancer
surgery and its influence on patients' score of Visual Analogue Scale (VAS). Methods One hundred and thirty patients with cervical
cancer surgically treated at First Hospital, Nanyang Medical College from May
2021 to May 2022 were selected as the research objects, and were divided into
an experimental group and a control group by lottery, with 65 cases in each
group. The experimental group were (45.36±1.17) years old, with a disease
course of (6.65±0.33) months. The control group were (45.11±1.46) years old,
with a disease course of (6.58±0.24) months. Both groups were given routine
anesthesia induction and maintenance anesthesia during operation.
Dexmedetomidine was used as auxiliary anesthesia during operation in the
experimental group. The VAS scores, intraoperative hemodynamics, postoperative
stress reaction, and adverse events after awakening were compared between the
two groups at different times. t and χ2 test were applied. Results The VAS score of the experimental group before
administration (T0) was not statistically different from that of the control
group [(2.52±0.11) vs. (2.55±0.42), t=0.557, P=0.578). The VAS scores immediately
(T1), 10 min (T2), and 30 min (T3) after administration, and after the
operation (T4) in the experimental group were lower than those in the control
group [(2.05±0.17) vs. (2.31±0.22), t=7.540, P<0.001; (1.82±0.33) vs.
(2.17±0.45), t=5.057, P<0.001; (1.55±0.35) vs. (1.92±0.46), t=5.161, P <0.001; (1.62±0.47) vs. (1.98±0.72), t=3.376, P<0.001]. The
oxygen saturation of blood (SpO2), arterial oxygen partial pressure
(PaO2), arterial blood carbon dioxide partial pressure (PaCO2),
and mean arterial pressure (MAP) were (98.44±0.27)%, (95.15±0.41) mmHg,
(35.22±1.45) mmHg, and (84.41±2.23) mmHg in the experimental group, and were
(98.62±0.74)%, (95.34±0.72) mmHg, (35.04±1.62) mmHg, and (84.15±2.12) mmHg in
the control group (t=1.842, P=0.068, t=1.849, P=0.065; t=0.668, P=0.506; and t=0.681, P=0.497). After the operation, the
levels of hydrogen peroxide (CAT), glutathione peroxidase (GSH-Px),
malonaldehyde (MDA), and cortisol (Cor)
and the incidence of postoperative adverse events were (7.32±0.26) U/ml,
(135.37±10.88) U/ml, (5.25±0.24) nmol/ml, (40.35±2.17) ng/ml, and 10.77% (7/65)
in the experimental group, and were (6.55±0.17) U/ml, (132.62±10.41) U/ml,
(6.44±0.62) nmol/ml, (43.37±2.26) ng/ml, and 7.69% (5/65) in the control group
(t=19.984, P<0.001; t=1.472, P<0.001; t=14.431, P<0.001; t=7.771, P<0.001; χ2=0.566, P=0.452). Conclusions Dexmedetomidine assisted anesthesia can enhance the analgesic effect of
cervical cancer patients during operation. This drug can ensure the stability
of hemodynamics during operation and reduce the risk of postoperative stress
and adverse events after awakening.